#ESMO26 Day 1 has arrived! Follow along with @OncoAlert for full coverage!
Highlights from the GU Renal & Urothelial Proffered Paper Session today:
🔴 Ph 3 KEYNOTE-866 (GC +/- perioperative pembro in MIBC)
🔴 Ph 3 ENERGIZE (GC +/- perioperative nivo in MIBC)
🔴 Ph 1 TROPHYU-01 Cohort 7 (SG + EV + Zim in 1L La/mUC)
🔴 ctDNA analyses from Ph 3 KEYNOTE-B15 (EV+P vs GC in cis-eligible MIBC)
Key❓: Why were KN-866 and ENERGIZE negative while NIAGARA was positive?
@scocmem @nataliagandur @DrKarineTawagi @niklas_kluemper @OncoAlert
373 浏览 · 6 赞 · 4 转发 · 0 回复
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.orgThe OncoAlert #ESMO26 PULSE Faculty is ready! 🇪🇸 WE ARE HERE! Meet our incredible faculty reporting live from Madrid: @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3 Whether you're at #ESMO26 in Madrid or following from home, our faculty will bring you the latest science, insights, and key updates straight from the congress. OncoAlert has you covered! Less noise. No nonsense. Just science. Strictly by colleagues, for colleagues!在 X 查看被引用的帖子
来源：Amanda Nizam, MD · x.com